Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
149.9 USD | -0.39% | -0.88% | -21.69% |
Financials (USD)
Sales 2024 * | 1.87B | Sales 2025 * | 2.26B | Capitalization | 18.96B |
---|---|---|---|---|---|
Net income 2024 * | -451M | Net income 2025 * | -257M | EV / Sales 2024 * | 9.45 x |
Net cash position 2024 * | 1.26B | Net cash position 2025 * | 475M | EV / Sales 2025 * | 8.18 x |
P/E ratio 2024 * |
-42.4
x | P/E ratio 2025 * |
-80.5
x | Employees | 2,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.59% |
Latest transcript on Alnylam Pharmaceuticals, Inc.
1 day | -0.39% | ||
1 week | -0.88% | ||
Current month | +4.13% | ||
1 month | +0.94% | ||
3 months | -7.48% | ||
6 months | -9.16% | ||
Current year | -21.69% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 16-09-18 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 19-08-12 |
Piyush Sharma
CMP | Compliance Officer | - | 22-09-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 15-12-17 |
Charles Sigal
BRD | Director/Board Member | 72 | 22-08-21 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 19-01-09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
5.08% | 1 M€ | -2.17% | - | |
4.04% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 149.9 | -0.39% | 512,792 |
24-05-10 | 150.5 | -0.59% | 322,795 |
24-05-09 | 151.4 | -0.60% | 329,246 |
24-05-08 | 152.3 | -1.32% | 452,321 |
24-05-07 | 154.3 | +2.06% | 353,438 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.69% | 18.96B | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+42.04% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B | |
+20.21% | 11.73B |
- Stock Market
- Equities
- ALNY Stock